Johan van Hylckama Vlieg - 05 May 2021 Form 3 Insider Report for Kaleido Biosciences, Inc.

Role
Chief Scientific Officer
Signature
/s/ Johan van Hylckama Vlieg
Issuer symbol
N/A
Transactions as of
05 May 2021
Net transactions value
$0
Form type
3
Filing time
13 May 2021, 08:38:30 UTC
Next filing
02 Sep 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KLDO Stock Option (Right to Buy) 05 May 2021 Common Stock 125,000 $7.67 Direct F1
holding KLDO Stock Option (Right to Buy) 05 May 2021 Common Stock 55,000 $6.56 Direct F2
holding KLDO Stock Option (Right to Buy) 05 May 2021 Common Stock 40,000 $6.00 Direct F3
holding KLDO Stock Option (Right to Buy) 05 May 2021 Common Stock 40,000 $8.69 Direct F4
holding KLDO Stock Option (Right to Buy) 05 May 2021 Common Stock 40,000 $9.81 Direct F5
holding KLDO Restricted Stock Units 05 May 2021 Common Stock 6,707 $0.000000 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option vested on July 1, 2020 with the remainder vesting in 12 equal quarterly installments thereafter.
F2 25% of this option vested on November 15, 2020 with the remainder vesting in 12 equal quarterly installments thereafter.
F3 25% of this option vested on April 15, 2021 with the remainder vesting in 12 equal quarterly installments thereafter.
F4 25% of this option will vest on October 15, 2021 with the remainder vesting in 12 equal quarterly installments thereafter.
F5 25% of this option will vest on March 1, 2022 with the remainder vesting in 12 equal quarterly installments thereafter.
F6 Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
F7 The restricted stock units will vest 100% on February 28, 2022.